Cancer chemotherapy targeted to angiogenic vessels is expected to cause indirect tumor regression through the damage of the neovasculature without the induction of drug resistance. To develop a tool for neovasculaturespeci®c drug delivery, we isolated novel peptides homing to angiogenic vessels formed by a dorsal air sac method from a phage-displayed peptide library. Three distinct phage clones that markedly accumulated in murine tumor xenografts presented PRPGAPLAGSWPGTS-, DRWRPALPVVLFPLH-or ASSSYPLIHWRPWARpeptide respectively. After the determination of the epitope sequences of these peptides, we modi®ed liposomes with epitope penta-peptides. Liposome modi®ed with APRPG-peptide showed high accumulation in murine tumor xenografts, and APRPG-modi®ed liposome encapsulating adriamycin eectively suppressed experimental tumor growth. Finally, speci®c binding of APRPG-modi®ed liposome to human umbilical endothelial cells, and that of PRP-containing peptide to angiogenic vessels in human tumors, i.e., islet cell tumor and glioblastoma, were demonstrated. The present study indicates the usefulness of APRPG-peptide as a tool for anti-neovascular therapy, a novel modality of cancer treatment.
Introduction
After the discovery of angiostatin (O'Reilly et al., 1996) , tumor dormancy therapy became a possible modality; and many attempts have been made to develop angiogenesis inhibitors. Anti-angiogenic drugs are thought to be free of severe side eects that are usually seen with cytotoxic anticancer drugs (Boehm et al., 1997) . Furthermore, anti-angiogenic therapy is thought not only to eradicate primary tumor tissues, but also suppress tumor metastases (Skobe et al., 1997) . Besides anti-angiogenic therapy, anti-neovascular therapy, i.e. indirect lethal damage of tumor cells through the damage of newly formed blood vessels, is also promising. Cytotoxic anticancer drugs cause damage to growing neovascular endothelial cells as well as tumor cells. Although tumor cells often acquire drug-resistance, neovascular endothelial cells would not be expected to acquire drug-resistance. Recently, it was suggested that cancer chemotherapy using anti-neovascular scheduling induced endothelial cell apoptosis prior to tumor cell apoptosis in tumor tissues and eradicated the tumor cells (Browder et al., 2000) . In addition, anti-neovascular-scheduled chemotherapy combined with angiogenesis inhibitor eradicated even the drug-resistant tumor cells (Browder et al., 2000) .
Furthermore, tumor angiogenic vasculature is thought to be an ideal target site for a drug delivery system (Brown and Giaccia, 1998; Langer, 1998; Zetter, 1997) . Newly formed blood vessels have the characteristics of high permeability induced by vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF), and macromolecules such as liposomes are known to passively accumulate in tumor tissues as a re¯ection of the feature (Asai et al., 1998; Oku, 1999a) . On the other hand, angiogenesis consists of a complex process involving the recruitment of endothelial progenitor cells (Asahara et al., 1997 (Asahara et al., , 1999 Ito et al., 1999) , as well as proliferation, migration and capillary formation by activated-endothelial cells. Since several growth factors, matrix metalloproteases, and adhesion molecules are involved in these steps, activated-endothelial cells express several speci®c marker molecules that are not or little expressed on preexisting vessels (St Croix et al., 2000) . These distinct marker molecules may provide active targeting guides for anti-angiogenic therapy and for anti-neovascular therapy.
In the present study, we isolated peptides speci®c for tumor angiogenic vasculature using a phage-displayed peptide library (Scott and Smith, 1990) . In general, biopanning of a phage-displayed peptide library is performed in vitro: The desired short peptide-expressing phages are isolated by their ability to bind to speci®c antibodies (Ishikawa et al., 1998; Takikawa et al., 2000) , proteins (Gho et al., 1997; Healy et al., 1995; Koivunen et al., 1993) , or glycoconjugates (Martens et al., 1995) . On the other hand, Pasqualini and Ruoslahti (1996) developed a strategy of in vivo biopanning: The phage-displayed peptide library is directly injected into the bloodstream of animals to isolate speci®c peptideexpressing phage clones homing to the desired organ. By this method, they isolated RGD-containing peptideexpressing phage clones after injection of the phagedisplayed peptide library into tumor-bearing mice (Arap et al., 1998; Pasqualini et al., 1997) . In here, we injected a phage-displayed peptide library into angiogenesis model mice prepared by the dorsal air sac (DAS) method (Kurohane et al., 2001 ) instead of tumor-bearing mice, and isolated phage clones speci®-cally accumulated in angiogenic site. The advantage of this method is that the selected phages have the ability to bind only to angiogenic vessels, not to tumor cells. In fact, the amino acid sequences of the phage clones thus obtained were dierent from any reported sequences obtained by in vivo biopanning with tumorbearing mice. The selected phage clones had high anity to murine angiogenic vessels. Then, we apply the peptide as a drug delivery system to the neovasculature. Our results demonstrated that antineovascular therapy using liposome modi®ed with the novel peptide markedly suppressed tumor growth possibly through cytotoxic eect of the encapsulated drug against angiogenic endothelial cells. Finally, confocal microscopic observation and histochemical staining demonstrated the applicability of the peptide obtained here to human.
Results

Isolation of the peptides homing to angiogenic vessels
We performed biopanning of the phage-displayed peptide library in DAS model mice in a total of ®ve rounds. At the ®fth round of biopanning, the recovery rate of the phage (recovered phage titer to input phage titer) increased about 1000-fold over that of the ®rst round (data not shown), suggesting that selection of high-anity phage clones capable of accumulating in the angiogenic site was successful. After cloning the selected phages, we performed sequencing of the peptides expressed on 13 selected phage clones. Five out of thirteen clones showed the same sequence, and some amino acid sequences of the other eight clones showed several partial homologies (Table 1) . To select phage clones having high anity for tumor angiogenic vasculature, we injected each phage clone intravenously into tumor-bearing mice and examined their capability to accumulate in the tumor. In this experiment, we used implanted tumors instead of the DAS model, since anity-selected phage clones against angiogenic vasculature would be expected to accumulate in the tumor tissue. In case of injection into B16BL6 melanoma-bearing mice, PRPGAPLAGSWPGTS, DRWRPALPVVLFPLH, and ASSSYPLIHWRPWAR peptide-presented phage clones accumulated in the tumor more than 20-fold compared with the accumulation of the original phage library (Table 1) . These clones also accumulated in Meth A sarcoma xenografts (Table 1) . To con®rm the capability of the synthetic peptides to accumulate in the tumor, we co-injected selected phage clones and corresponding synthetic pentadecapeptides into B16BL6 melanoma-bearing mice. Tumor accumulation of each phage clone was suppressed in the presence of the corresponding 15 mer peptide, although a random 15 mer peptide, GLDLLGDVRIPVVRR, did not aect the phage accumulation (Table 2) .
APRPG-modified liposome accumulates in murine tumor xenografts
Next, we determined the epitope sequences of the peptides. DRWRPALPVVLFPLH and ASSSY-PLIHWRPWAR, which contain the common sequence of WRP, showed cross-reactivity (Table 2 ). In view of these ®ndings, we synthesized fragment peptides focusing on the WRP sequence, and examined the inhibitory eect of these peptides against tumor accumulation of the corresponding phage clones. The fragment peptides containing WRP inhibited the accumulation of phages expressing full-length peptide containing WRP (Table 2) . Since PRPGAPLAGSWPGTS has a resembled sequence to WRP, namely PRP, we also focused on the PRP sequence and observed the inhibitory eect of the fragment peptide having N-terminus 8 mer, PRPGA-PLA, against the accumulation of PRPGA-PLAGSWPGTS-presented phage in tumors (Table 2) . Based on these results, we modi®ed liposomes with pentapeptides having PRP or WRP sequences and examined the biodistribution of these liposomes in tumor-bearing mice. All peptide-modi®ed liposomes showed high accumulativeness in tumor tissue compared with control liposome (Figure 1a ). In particular, APRPG-modi®ed liposome (PRP-Lip) showed the highest accumulation in tumors. PRP-Lip had another feature, namely, it tends to avoid trapping by the reticuloendothelial system such as the spleen and liver (data not shown). Next, we examined the eect of APRPG incorporation into liposome on their in vivo behavior using positron emission tomography (PET). A PET study allows us to analyse real time distribution change of liposomes under non-invasive conditions. The time activity curves of liposomes indicated that PRP-Lip tended to accumulate in tumor time dependently ( Figure  1b ). This result was con®rmed by the actual 18 F accumulation in the tumor, liver and spleen after PET scanning (data not shown).
Anti-neovascular therapy suppressed tumor growth
We then examined the suppression of tumor growth by the treatment of Meth A sarcoma-bearing mice with adriamycin (ADM), APRPG-modi®ed liposome encapsulating ADM (PRP-LipADM), and control liposome (Oku et al., 1994) . It is because passive targeting or active targeting of liposomes to tumor tissues is well achieved, when tumors induce angiogenic vasculature. Thus, enhanced ecacy of liposomalization are depending on the schedule of treatment, PRP-LipADM might get more potent ecacy by optimizing that of treatment. The results also indicate that liposomalization itself is useful for decreasing side eects, since both PRP-LipADM and LipADM did not cause noticeable body weight change but free ADMtreated mice decreased in body weight progressively (data not shown). In fact, all free ADM-treated animals died of acute toxicity at a dose of 10 mg/kg (data not shown). Such reduction of the side eect was well known by liposomalization. The mean survival time for the control, LipADM-treated, and PRP-LipADM treated mice were 38.8, 47.7 and 50.2 days, respectively. PRPLipADM was most ecient for prolonging survival time with an increased life span of about 30%. We also examined the suppression of tumor growth by PRPLipADM in Colon 26 NL-17-bearing mice. PRPLipADM also showed marked suppression against Colon 26 NL-17 (Figure 2b ). The free ADM treatment group lost weight and three of six mice died of toxicity. The mean survival time for the control, LipADMtreated, and PRP-LipADM treated mice were 55.8, 69.7 and 72.3 days, respectively. Again, PRP-LipADM was the most ecient (about 30% increase in life span), and one of six mice was completely cured. We next examined the eect of PRP-LipADM on tumor-induced angiogenic vessels. As a result, PRP-LipADM markedly damaged newly forming blood vessels (Figure 2c ). These results suggest that modi®cation of liposome with APRPG enhanced the anti-tumor activity of ADM and reduced toxicity of ADM due to targeting eect. Furthermore, PRP-Lip has a possibility as a carrier of agents for anti-neovascular therapy, or to deliver antiangiogenic agents to the angiogenic site.
Applicability of PRP-containing peptide to human
Finally we investigated whether the peptides selected in the murine angiogenic model have anity for angiogenic endothelium in human tumors. Binding capacity of PRPLip and control liposome to human umbilical endothelial cells (HUVECs) was determined with con-focal microscope. NBD-labeled liposome bound to VEGFactivated HUVECs only when liposome was modi®ed with APRPG ( Figure 3a,b) . This binding was cancelled in the presence of excess APRPG peptide (Figure 3c ). The speci®c binding of PRP-Lip was not observed without stimulation of HUVECs with VEGF ( Figure  3d) . Furthermore, histochemical analysis demonstrated that biotinylated PRPGAPLAGSWPGTS speci®cally bound to angiogenic endothelial cells in human islet cell tumor of the pancreas and glioblastoma (Figure 4a,b) . However, biotinylated peptide containing the WRP sequence, i.e., ASSSYPLIHWRPWAR, did not show the speci®c binding to endothelial cells in the islet cell tumor (data not shown). Pre-treatment with an excess of synthetic PRPGAPLAGSWPGTS inhibited the binding of biotinylated PRPGAPLAGSWPGTS in the glioblastoma tissue (Figure 4c ). These data indicate that PRPcontaining peptides have anity to some molecule(s) on human angiogenic endothelial cells.
Discussion
In general, cancer chemotherapy is accompanied by strong side eects and acquired drug resistance. Therefore, drug delivery systems that selectively deliver the drugs to the target tumor are awaited. Many Anti-neovascular therapy using novel peptide N Oku et al attempts have been made for this purpose including the usage of monoclonal antibodies against tumor tissues (Huang et al., 1997; Viti et al., 1999) . Recently, vascular targeting has become a focus of interest, since certain drugs or drug carriers ®rst meet neovasculature before extravasation in the tumor. Especially, targeting of a tumor angiogenic vasculature is promising for cancer treatment since these vessels have properties dierent from those of the preexisting systemic vasculature (Brower, 1999; Hanahan, 1997) . Here, we revealed that angiogenic vasculature-speci®c peptides, PRPGAPLAGSWPGTS or APRPG, might be useful as tools for active targeting to tumor neovasculature. Since we selected phage clones from DAS model mice instead of tumor-bearing mice, the selected amino acid sequences should be speci®c only for the angiogenic site but not for tumor tissues. Our results demonstrated that PRPGAPLAGSWPGTS-, DRWR-PALPVVLFPLH-, and ASSSYPLIHWRPWAR-presented phage clones highly accumulated in two types of murine tumor. These data indicate that the homing capability of these phages was independent of tumor type, supporting the idea that they were not recognized by any tumor cell-surface molecule(s), but by some angiogenesis-related molecule(s). The amino acid sequences of these peptides have not been isolated in other screenings. There was no candidate molecule with signi®cant homology to PRPGAPLAGSWPGTS and DRWRPALPVVLFPLH in a homology search, although the HWRPW sequence in ASSSYPLIHWRP-WAR revealed to be identical to a part of the sequence of Flt-4, a receptor for VEGF-C. VEGF-C is known to bind to Flk-1/KDR as well as to Flt-4, and is reported to be an angiogenesis stimulator (Cao et al., 1998) . The importance of the HWRPW sequence for the interaction of VEGF-C with its receptors, however, is not clear at present. The target molecule(s) of the novel peptides obtained here should be clari®ed in the future.
Liposomal homing study supports the idea that PRP and WRP sequences are important for the targeting to angiogenic sites, since two dierent particles carrying the sequence, namely, phage and liposomes, accumulated in tumor tissues, the former particle expressing the sequence, and the latter being modi®ed by the sequence. Such small peptides are known to bind to certain speci®c proteins. For example, RGD-related peptides are known to interact with integrin a5b1 and avb3. In fact, since the latter integrin is expressed on several tumor cells and angiogenic endothelium (Eliceiri and Cheresh, 1999), RGD-related peptides are reported to home in on the angiogenic endothelium of tumor-bearing mice after tail vein injection (Arap et al., 1998; Pasqualini et al., 1997) .
Liposomes modi®ed with pentapeptides having PRP or WRP showed high accumulativeness in the tumor. In particular, PRP-Lip showed the highest accumulation in the tumor. We also determined the biodistribution of liposomes modi®ed with well-known peptides such as GRGDS and non-speci®c peptides such as LFPLH, and the accumulation of these liposomes in tumor tissues was observed to be less than that of APRPG-modi®ed liposomes (data not shown). From the results of both biodistribution of liposomes and histochemical staining patterns of peptides, we decided to assess the eect of PRP-Lip as a drug carrier. We used 10 mol% peptide-containing liposome, because 5 or 10 mol% peptides-contained liposomes showed no signi®cant dierences in their biodistribution to 20 mol% peptide-modi®ed liposomes (data not shown). Before in vivo therapeutic experiments, we determined the stability of LipADM and PRP-LipADM in the presence or absence of serum. These liposomes did not make aggregates in the presence of 50% serum. Furthermore, ADM release was not observed for at least 48 h from both liposomes in the presence of 50% serum, suggesting that these liposomes are quite stable during circulation in vivo (data not shown). These data suggest that peptide coating did not aect the physical properties of liposomes. In therapeutic experiments, modi®cation of liposome with APRPG enhanced the anti-tumor activity of ADM and the reduced toxicity of it due to targeting eect. These eects of APRPG were independent of tumor type. Stability of PRPLipADM suggests that these enhanced therapeutic ecacies did not cause the non-speci®c alteration of liposomes by peptide coating. The anti-tumor activity of PRP-LipADM may be explained partly by the increase of local concentration of ADM in the tumor. Although, we speculate that ADM damaged neovascular endothelial cells, since PRP-LipADM is expected to bind these growing cells eciently from the results of both confocal observation and histochemical staining. However, further experiments are required for elucidating which factor is predominant between direct toxicity against tumor cells and indirect tumor growth suppression through toxic action against angiogenic endothelial cells. Taken together, it would be expected that PRP-Lip could deliver anticancer agents for anti-neovascular therapy, or anti-angiogenic agents for tumor dormancy therapy. Direct conjugation of the peptides with anticancer agents or angiogenesis inhibitors would also be possible for the purpose of anti-neovascular or anti-angiogenic therapy. Furthermore, it is considered that APRPG may be useful for human cancer treatment, since we demonstrated that PRP-Lip and PRPGAPLAGSWPGTS have anity for VEGF-stimulated HUVECs and human tumor angiogenic endothelia, respectively.
Materials and methods
In vivo biopanning and screening DAS model mice were prepared according to a modi®ed method described previously (Kurohane et al., 2001) . In brief, highly metastatic murine B16BL6 melanoma cells (1610 7 cells/ring) were loaded into a Millipore chamber ring (Millipore Co., Bedford, MA, USA). The chamber rings were dorsally implanted into 5-week-old C57BL/6 male mice (Japan SLC Inc., Shizuoka, Japan). Five days after the implantation, these mice were used for in vivo biopanning.
A phage-displayed random peptide library expressing pentadecapeptides at the N terminus of pIII coat protein of M13 phage was kindly provided by Dr Hideyuki Saya of Kumamoto University (Nishi et al., 1996) . In vivo biopanning was performed by a modi®ed method as described by Pasqualini et al. (1997) . In brief, 1.0610 13 colony-forming unit (c.f.u.) of the phage-displayed peptide library was injected into DAS model mice via a tail vein. Four minutes after injection, the phages that had accumulated in angiogenic vessels were recovered and titrated. Biopanning steps were repeated for ®ve cycles. After selected phages were cloned, sequences of the peptides presented were determined as described previously (Ishikawa et al., 1998; Takikawa et al., 2000) . For anity screening, B16BL6 cells (1.0610 6 cells/ mouse) were implanted subcutaneously into the posterior ank of 5-week-old C57BL/6 male mice. Each sample of phage clones (1.0610 11 c.f.u.) was injected into tumorbearing mice via a tail vein when the tumor size had become about 10 mm in diameter. Four minutes after injection, the phages that had accumulated in tumor tissue were recovered and titrated.
Peptides were synthesized using Rink amide resin (0.4 ± 0.7 mmol/g) with the peptide synthesizer ACT357 (Advanced ChemTech). To examine the inhibitory eect of the synthetic peptide against phage accumulation, puri®ed phage clone (5610 8 c.f.u.) and 0.25 mmol of each synthetic peptide were co-injected into tumor-bearing mice. Four minutes after injection, the titer of phages recovered from the tumor tissue was determined.
Biodistribution study
Meth A sarcoma or Colon 26 NL-17 carcinoma cells (1.0610 6 cells/mouse) were injected subcutaneously into the posterior¯ank of 5-week-old Balb/c male mice (Japan SLC Inc.), and biodistribution study was performed when the tumor size had become about 10 mm in diameter. Liposome composed of distearoylphosphatidylcholine (DSPC, gift from Nippon Fine Chemical Co. Ltd., Hyogo, Japan), cholesterol (Sigma, St. Louis, MO, USA), and stearoyl 5 mer peptide (APRPG, RWRPA or HWRPW), 10/5/2 as a molar ratio, was prepared, sized at 100-nm by extrusion through a pored ®lter, and radiolabeled with [oleate-1-14 C]cholesteryl-oleate (74 kBq/mouse, Amersham Pharmacia, Buckinghamshire, UK) as described previously (Oku et al., 1992) . Size-matched Meth A sarcoma-or Colon 26 NL-17 carcinoma-bearing mice were injected with the radiolabeled liposomes via a tail vein. Three hours after the injection, the mice were sacri®ced under diethyl ether anesthesia for the collection of the blood. After the mice had been bled from the carotid artery, the heart, lung, liver, spleen, kidney, and tumor were removed, washed with saline, and weighed. The radioactivity in each organ was determined with a liquid scintillation counter (Aloka, LSC-3500).
PET study
For positron emission tomography (PET) study, liposomes composed of DSPC: cholesterol=2 : 1 (control liposome) or DSPC : cholesterol : stearoyl APRPG=20 : 10 : 1 (PRP-Lip) as a molar ratio were prepared, sized at 100-nm, and loaded with [2-
18 F]2-¯uoro-2-deoxy-D-glucose. Then, liposomal traf- ®cking in tumor bearing mice was analysed by PET as described previously (Asai et al., 1998; Oku, 1999b) . In brief, Colon 26 NL-17 bearing Balb/c mice were anesthetized and injected via a tail vein with 18 F-labeled liposomes. The emission scan was started immediately after injection and performed for 120 min with an animal PET camera (Hamamatsu Photonics, SHR-7700). Time-activity curves were obtained from the mean pixel radioactivity in the region of interest (ROI) of the PET images. After the PET scan, the mice were sacri®ced, and the biodistribution of 18 F was con®rmed with a gamma-well scintillation counter.
Anti-tumor (anti-neovascular) activity of ADM-encapsulated neovasculature-homing liposome Adriamycin (ADM)-encapsulated liposomes were prepared by a modi®cation of the remote-loading method as described previously (Oku et al., 1994) , and the encapsulation eciency was more than 90% throughout the experiment. The liposomal size and composition were the same as the PET study. Tumor implantation was performed as described above. ADM-encapsulated in the control liposome (LipADM) or in liposome-modi®ed with stearoyl APRPG (PRP-LipADM) (10 mg/kg as ADM), ADM alone (10 mg/ kg), or 0.3 M glucose (control) were injected intravenously into tumor-bearing mice at days 6, 9 and 12 after implantation of Meth A sarcoma, or at days 9, 12 and 15 after implantation of Colon 26 NL-17 carcinoma cells. The sizes of the tumor and body weight of each mouse were monitored everyday. Tumor volume was calculated using the formula 0.4 (a6b 2 ), where`a' was the largest and`b' was the smallest diameter of the tumor. Variance in a group was evaluated by the F-test, and dierences in mean tumor volume were evaluated by Student's t-test.
For assay of anti-neovascular activity, a chamber ring loaded with Colon 26 NL-17 cells (1610 7 cells/ring) was dorsally inoculated into Balb/c male mice. At 2 days after inoculation, LipADM, PRP-LipADM (10 mg/kg as ADM), ADM alone (10 mg/kg) or 0.3 M glucose were injected intravenously into DAS model mice. At 4 days after inoculation, 1% Evans Blue solution was injected intravenously into them. After 1 min, they were sacri®ced and the pigment in the skin attached to the ring was extracted for the measurement of absorbance at 620 nm.
Confocal observation
NBD-phosphatidylethanolamine (NBD-PE)-labeled liposomes composed of DSPC: cholesterol: NBD-PE=20 : 10 : 1 (control liposome) or DSPC : cholesterol : stearoyl APRPG : NBD-PE=20 : 10 : 2 : 1 (PRP-Lip) as a molar ratio were prepared. HUVECs pre-treated with 100 ng/ml VEGF for 24 h were incubated with control liposomes or PRP-Lip for 30 min. To con®rm the speci®c binding of PRP-Lip, HUVECs were incubated with PRP-Lip in the presence of 20-fold excess of free APRPG-peptides. HUVECs without stimulation of VEGF were also incubated with PRP-Lip. Then, HUVECs were washed with phosphate-buered saline (PBS) and ®xed with 2% paraformaldehyde ± 0.2% glutaraldehyde in PBS. Localization of liposomes was monitored using LSM510 confocal system (Carl Zeiss Co., Ltd.).
Histochemical analysis
Biotinylated pentadecamer peptides were synthesized and used for histochemical analysis. Fresh tumor samples were obtained from patients with islet cell tumor of the pancreas or glioblastoma of the brain operated on Shinshu University Hospital, Matsumoto, Japan after informed consents were obtained. These samples were embedded in OCT compound, and frozen sections were ®xed with 20% buered formalin for 15 min. The formalin-®xed specimens were treated with 0.3% H 2 O 2 in absolute methanol for 30 min. After washing, the specimens were incubated with 200 mg/ml biotinylated peptides solution in 48C overnight and immersed in a horseradish peroxidase-labeled strep- To determine the speci®city of binding, adjacent sections of the specimens were incubated with excess synthetic peptides prior to the addition of biotinylated peptides. The peroxidase activity was developed in a diaminobenzidine-hydrogen peroxide solution. Cell nuclei were counterstained with Mayer's hematoxylin.
